Series A & B
for further investments
Momotaro-gene (MTG) develops gene therapy products to treat solid cancer based on MTG’s proprietary adenoviral vector technology platform to deliver the Reduced Expression in Immortalized Cells/Dickkopf-3 gene (REIC/Dkk-3 gene) into cancer cells, where the expression of the gene has been shown to be markedly downregulated. The resulting increase in REIC/Dkk-3 gene expression in cancer cells triggers immunogenic cell death selectively in cancer cells. At the same time, secreted REIC/Dkk-3 proteins by cancer cells and normal cell components in tumor tissue promotes anti-tumor immunity by activating dendritic cells and natural killer (NK) cells. Based on these novel dual mechanisms, MTG is expanding its pipelines with successful clinical studies. BiGEN participated in Series A fundraising in 2017.http://www.mt-gene.com
A Japanese Biotech is a biotech company that develops cell therapy products using its unique technology of inducing immunotolerance in patients who undergo liver or kidney transplantation. A Japanese Biotech’s regenerative medicine is autologous T cells cultured with donor T cells and antibodies. The autologous T cells can obtain the ability to induce immunotolerance to donor derived organs, which allows reduction or discontinuation of immunosuppressant after organ transplant. BiGEN participated in Series A fundraising in 2018.
Noile-Immune Biotech (NIB) focuses on the development and commercialization of next generation CAR-T cells targeting solid cancers. NIB develops the PRIME (PRoliferation-Inducing and Migration-Enhancing) CAR-T technology secreting IL-7 and CCL19. The PRIME technology improves proliferation and trafficking into solid cancers of not only CAR-T cells but also patient’s endogenous immune cells. BiGEN participated in Series A fundraising in 2018 and Series B fundraising in 2020.https://www.noile-immune.com/
ProJect Pharmaceutics located in Germany provides top-tier service in developing pharmaceutical formulation for recombinant proteins, ADCs, cytotoxics, and live virus vaccines. ProJect Pharmaceutics also offers cost-effective fill and finish services for IMPs.
If you are interested in PJP’s service in Asia, please click Servicehttps://project-pharmaceutics.com/
Binex, a Contract Development and Manufacturing Organization located in S.Korea, provides full range services from cell line development to GMP manufacturing for drug substance and drug product. CDMO services offered by Binex covers sophisticated analytic services and cGMP manufacturing for IMPs and commercial products (mAb/recombinant protein), leading to successful approval for INDs and BLAs of clients’ project.http://bi-nex.com
Rhinos is a distinguished and dominant private asset management company in Korea. Based upon its management philosophy of pursuing stability, Rhinos has achieved lots of successful investment outputs and is actively expanding investment tracks together with its reliable partners including major LPs in Korea. BiGEN and Rhinos are collaborating with each other to maximize the synergic effect in the area of investment by closely sharing expertise and information in bio-industry and finance sector.https://www.rhinos.kr/